Initial Statement of Beneficial Ownership (3)
January 12 2022 - 5:14PM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0104
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
|
1. Name and Address of Reporting Person
*
Bandari Jathin |
2. Date of Event Requiring Statement (MM/DD/YYYY)
1/10/2022
|
3. Issuer Name and Ticker or Trading Symbol
Protara Therapeutics, Inc. [TARA]
|
|
(Last)
(First)
(Middle)
C/O PROTARA THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, 3RD FLOOR |
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
_____ Director _____ 10% Owner
___X___ Officer (give title below) _____ Other (specify below)
Chief Medical Officer / |
|
(Street)
NEW YORK, NY 10010
(City)
(State)
(Zip)
| 5. If Amendment, Date Original Filed(MM/DD/YYYY)
| 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Beneficially Owned
|
1.Title of Security
(Instr. 4) | 2. Amount of Securities Beneficially Owned
(Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5) | 4. Nature of Indirect Beneficial Ownership
(Instr. 5) |
| Common Stock | 7500 (1) | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 4) | 2. Date Exercisable and Expiration Date
(MM/DD/YYYY) | 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5) | 6. Nature of Indirect Beneficial Ownership
(Instr. 5) |
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
| Stock Option (right to buy) | (2) | 6/30/2030 | Common Stock | 14500 | $28.20 | D | |
| Stock Option (right to buy) | (3) | 8/31/2030 | Common Stock | 2500 | $20.51 | D | |
| Stock Option (right to buy) | (4) | 1/18/2031 | Common Stock | 13877 | $19.82 | D | |
| Stock Option (right to buy) | (4) | 1/18/2031 | Common Stock | 11123 | $19.82 | D | |
| Stock Option (right to buy) | (5) | 9/30/2031 | Common Stock | 523 | $6.95 | D | |
| Stock Option (right to buy) | (5) | 9/30/2031 | Common Stock | 1977 | $6.95 | D | |
| Stock Option (right to buy) | (6) | 10/31/2031 | Common Stock | 1355 | $7.02 | D | |
| Stock Option (right to buy) | (6) | 10/31/2031 | Common Stock | 5145 | $7.02 | D | |
| Explanation of Responses: |
| (1) | The shares reported are issued pursuant to a restricted stock unit award (RSU), of which represents a contingent right to receive one share of Issuer's common stock. The RSU vest in equal one-fourth installments on the first, second, third and fourth anniversaries of July 1, 2020. |
| (2) | 25% of the shares vest on the one year anniversary of July 1, 2020 and 1/48th of the shares vest monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date. |
| (3) | 25% of the shares vest on the one year anniversary of September 1, 2020 and 1/48th of the shares vest monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date. |
| (4) | 25% of the shares vest on the one year anniversary of January 19, 2021 and 1/48th of the shares vest monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date. |
| (5) | 25% of the shares vest on the one year anniversary of October 1, 2021 and 1/48th of the shares vest monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date. |
| (6) | 25% of the shares vest on the one year anniversary of November 1, 2021 and 1/48th of the shares vest monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date. |
Reporting Owners
|
| Reporting Owner Name / Address | Relationships |
| Director | 10% Owner | Officer | Other |
Bandari Jathin
C/O PROTARA THERAPEUTICS, INC.
345 PARK AVENUE SOUTH, 3RD FLOOR
NEW YORK, NY 10010 |
|
| Chief Medical Officer |
|
Signatures
|
| Mary Grendell, Attorney-in-Fact | | 1/10/2022 |
| **Signature of Reporting Person | Date |
Protara Therapeutics (NASDAQ:TARA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Protara Therapeutics (NASDAQ:TARA)
Historical Stock Chart
From Jul 2023 to Jul 2024
